Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Page 1
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.
Gascón P, Nagarkar R, Šmakal M, Syrigos KN, Barrios CH, Sánchez JC, Zhang L, Henry DH, Gordon D, Hirsh V, Kubota K, Orlov S, Thomas G, Steinmetz T, Kang JH, Tomita DK, Fleishman AN, Park JK, De Oliveira Brandao C. Gascón P, et al. Among authors: henry dh. J Thorac Oncol. 2020 Feb;15(2):190-202. doi: 10.1016/j.jtho.2019.10.005. Epub 2019 Oct 16. J Thorac Oncol. 2020. PMID: 31629060 Free article. Clinical Trial.
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.
Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore PC, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A. Bayraktar UD, et al. Among authors: henry dh. Leuk Lymphoma. 2012 Dec;53(12):2383-9. doi: 10.3109/10428194.2012.697559. Epub 2012 Jul 9. Leuk Lymphoma. 2012. PMID: 22642936 Free PMC article.
However, among 32 patients (36%) who achieved a complete or partial response (CR/PR) after second-line therapy, 1-year OS was not different between the two groups (87.5% for ASCT vs. 81.8% for non-ASCT). Long-term survival in some patients with rel/rfr ARL may be possible …
However, among 32 patients (36%) who achieved a complete or partial response (CR/PR) after second-line therapy, 1-year OS was not different …
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Kuter DJ, et al. Among authors: henry dh. Lancet. 2008 Feb 2;371(9610):395-403. doi: 10.1016/S0140-6736(08)60203-2. Lancet. 2008. PMID: 18242413 Clinical Trial.
BACKGROUND: Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet destruction and decreased platelet production. Short-term administration of the thrombopoiesis-stimulating protein, romiplostim, has been shown to increase platelet counts in …
BACKGROUND: Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet destruction and decreased platelet produc …
Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma.
Weese JL, Harbison SP, Stiller GD, Henry DH, Fisher SA. Weese JL, et al. Among authors: henry dh. Surgery. 2000 Oct;128(4):564-71. doi: 10.1067/msy.2000.108420. Surgery. 2000. PMID: 11015089 Clinical Trial.
CONCLUSIONS: Neoadjuvant multimodality therapy with neoadjuvant 5-fluorouracil, Leucovorin, Adriamycin, and Cisplatin, radical resection with IORT, and postoperative radiation therapy is safe, can downstage tumors, provides improved locoregional control, and appears to cause sign …
CONCLUSIONS: Neoadjuvant multimodality therapy with neoadjuvant 5-fluorouracil, Leucovorin, Adriamycin, and Cisplatin, radical resection wit …
Minimal toxicity during protein A immunoadsorption treatment of malignant disease: an outpatient therapy.
Snyder HW Jr, Henry DH, Messerschmidt GL, Mittelman A, Bertram J, Ambinder E, Kiprov D, Balint JP Jr, MacKintosh FR, Hamburger M, et al. Snyder HW Jr, et al. Among authors: henry dh. J Clin Apher. 1991;6(1):1-10. doi: 10.1002/jca.2920060102. J Clin Apher. 1991. PMID: 2045375 Clinical Trial.
Treatment schedules were interrupted due to side effects for only six patients and there were no treatment-related deaths. Of 64 patients available for long-term follow-up evaluation (mean of 11 months), none exhibited evidence of long-term treatment-related side ef …
Treatment schedules were interrupted due to side effects for only six patients and there were no treatment-related deaths. Of 64 patients av …